Showing results (51-60 of 59) with videos related to
Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 59 results.
Nature Communications|August 28, 2020
Enhancing intracellular accumulation and target engagement of PROTACs with reversible covalent chemistryWen-Hao Guo, Xiaoli Qi, Xin Yu, et al.Biomolecules|March 1, 2019
Structural and Dynamical Order of a Disordered Protein: Molecular Insights into Conformational Switching of PAGE4 at the Systems LevelXingcheng Lin, Prakash Kulkarni, Federico Bocci, et al.Cancers|March 11, 2023
A Phase 2 Trial of Ibrutinib and Nivolumab in Patients with Relapsed or Refractory Classical Hodgkin's LymphomaWalter Hanel, Polina Shindiapina, David A Bond, et al.Journal of Hematology & Oncology|May 9, 2023
Impact of early relapse within 24 months after first-line systemic therapy (POD24) on outcomes in patients with marginal zone lymphoma: A US multisite studyNarendranath Epperla, Rina Li Welkie, Pallawi Torka, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 12, 2025
Azacitidine, Venetoclax, and Revumenib for Newly Diagnosed <i>NPM1</i>-Mutated or <i>KMT2A</i>-Rearranged AMLJoshua F Zeidner, Tara L Lin, Rina Li Welkie, et al.Haematologica|November 6, 2025
<i>IDH2</i> mutation is associated with favorable outcome among older adults with newly diagnosed acute myeloid leukemia treated with hypomethylating agent-based therapyFieke W Hoff, Ying Huang, Rina Li Welkie, et al.Blood Advances|August 7, 2024
Beat-AML 2024 ELN-refined risk stratification for older adults with newly diagnosed AML given lower-intensity therapyFieke W Hoff, William G Blum, Ying Huang, et al.American Journal of Hematology|July 3, 2026
Signaling Mutations Negate the Favorable Impact of NPM1 Mutations in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With VEN/HMAFieke W Hoff, Joshua F Zeidner, Geeta Torlapati, et al.Blood|March 27, 2025
Reducing clinical trial eligibility barriers for patients with MDS: an icMDS position statementUma Borate, Kelly Pugh, Allyson Waller, et al.Pageof 6